GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech Showcase coinciding with the 42^nd Annual J.P. Morgan Healthcare Conference in San Francisco, January 8-11, 2024.

Presentation Details:
Presenter:        David Dodd, Chairman & CEO
Date/Time:       January 8, 2023, 2:30 pm PST
Location:          Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA
Registration:     Biotech Showcase

A live webcast of the presentation will be available here.  A replay will be available approximately 2 hours after the presentation and accessible for three months.

Additionally, senior management of GeoVax will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. One-on-one appointments may be requested as follows:

• Through the Biotech Showcase partnering platform here.  
• Through the Biotechnology Innovation Organization (BIO) partnering platform here.
• Direct outreach to the Company at info@geovax.com or to SternIR at maxmilian.gadicke@sternir.com

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.